Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04597437
PHASE2

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Sponsor: George Washington University

View on ClinicalTrials.gov

Summary

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.

Official title: Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial

Key Details

Gender

All

Age Range

7 Years - Any

Study Type

INTERVENTIONAL

Enrollment

74

Start Date

2024-03-15

Completion Date

2026-09-30

Last Updated

2025-07-28

Healthy Volunteers

No

Conditions

Interventions

DRUG

Zanamivir

Intravenous zanamivir

OTHER

Placebo

In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

Locations (2)

Cien Salud IPS SAS

Barranquilla, Atlántico, Colombia

Clinica de la Costa SAS

Barranquilla, Colombia, Colombia